Related references
Note: Only part of the references are listed.Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan
Masamichi Isobe et al.
ANNALS OF HEMATOLOGY (2021)
Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type
Takaaki Konuma et al.
CLINICAL CANCER RESEARCH (2021)
Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation
Chikako Ohwada et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2021)
Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies
Naoyuki Uchida et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2020)
Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients
Masamitsu Yanada et al.
LEUKEMIA & LYMPHOMA (2018)
Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients
B. S. Andersson et al.
BONE MARROW TRANSPLANTATION (2017)
Impact of graft-versus-host disease on outcomes after unrelated cord blood transplantation
J. Kanda et al.
LEUKEMIA (2017)
Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older
Koji Kawamura et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)
Yoshiko Atsuta
INTERNATIONAL JOURNAL OF HEMATOLOGY (2016)
Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission
John M. Magenau et al.
ANNALS OF HEMATOLOGY (2015)
Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Mohamed A. Kharfan-Dabaja et al.
LEUKEMIA RESEARCH (2015)
Favorable outcomes of tacrolimus compared with cyclosporine A for GVHD prophylaxis in HSCT for standard-risk hematological diseases
Ryo Nasu et al.
ANNALS OF HEMATOLOGY (2014)
Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT
M. A. Kharfan-Dabaja et al.
BONE MARROW TRANSPLANTATION (2014)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation
Rohtesh S. Mehta et al.
Clinical Lymphoma Myeloma & Leukemia (2013)
Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity
J. Pidala et al.
BONE MARROW TRANSPLANTATION (2011)
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning
Mehdi Hamadani et al.
HEMATOLOGICAL ONCOLOGY (2011)
Busulfan in Hematopoietic Stem Cell Transplantation
Stefan O. Ciurea et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Reduced-intensity conditioning and umbilical cord blood transplantation in adults
C. Cutler et al.
BONE MARROW TRANSPLANTATION (2009)
Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients
Mitcbell E. Horwitz et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS
Borje S. Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Chronic graft-versus-host disease following umbilical cord blood transplantation: retrospective survey involving 1072 patients in Japan
Hiroto Narimatsu et al.
BLOOD (2008)
Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP system
Yoshiko Atsuta et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2007)
New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2
Y. S. Chae et al.
BONE MARROW TRANSPLANTATION (2007)
Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan
Tsunehiko Komatsu et al.
ANNALS OF HEMATOLOGY (2007)
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
M de Lima et al.
BLOOD (2004)
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia
BS Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)
Share Paper
